The Elderly End of Life
|
|
- Sheena Oliver
- 5 years ago
- Views:
Transcription
1 The Elderly End of Life
2 Heart failure is a disease of the elderly Many patients with heart failure now survive to die of other diseases. There is a pyramid of decisions before resuscitation. Tough discussions today make difficult situations easier ahead.
3 Annual Rates of Heart Failure Discharge By Age Per 1,000 Population * Average Age in Trials * * * > 75 Men Women National Hospital Discharge Survey, CDC/NCHS
4 HF at 5 yrs post MI Mortality p MI From Acute MI to Chronic Heart Failure
5 The elderly will not be undergoing the disease- exchanging interventions of heart transplantation or mechanical circulatory support devices.
6 Mechanical Circulatory Support Pulsatile Axial Centrifugal HeartMate XVE HeartMate II CentriMag Thoratec PVAD Heartware HVAD TandemHeart PVAD
7
8 Heart Failure Hospitalizations by LVEF LVEF < 40% 40-55% >55% Sweitzer et al ACC 2005 For the ADHERE Registry Yancy et al JACC ; % patients with dyspnea at rest or minimal exertion 30% with GI symptoms
9 Symptomatic Heart Failure Therapy by LVEF More The Same Than Different Treat congestion Fluid balance HF management Exercise Planning desired activities Better monitoring Cardio-renal limits Palliative care
10 Cumulative Mortality Mortality Increases with Repeated HF Hospitalization Total number of death= 7,401 4 th admission 3 rd admission 2 nd admission 41 th st admission Setoguchi et al American Heart Journal Time Since HF Admission (years)
11 Medial Survival (years) Median Survival After Repeated Hospitalizations Similar With and Without Sudden Death Prevention in Community Population 3.0 Estimated GFR < st hospitalization (n=14,374) 2nd hospitalization (n=3,358) 3rd hospitalization (n=1,123) 4th hospitalization (n=417) Setoguchi et al. AHJ 2007
12 Death and Heart Failure Sudden Death Non-sudden Death Sudden death proportion decreases with HF severity. Non-cardiac non-sudden Increases with older age
13 Deaths After First Heart Failure Hospitalization in Community 14,374 pts in British Columbia 7401 deaths at mean 1.7 mean years after 1 st hosp 62% Mean Age = 77 years In Hosp Card Non-cardiac 22% 16% Cardiac in Long-term Care 9% 7% Sudden during Independent Living Only 7% of deaths occur suddenly out of hospita during independent living Setoguchi et al, AHA 2006
14 What Does the Patient with Heart Failure Want?
15 Heart Failure Population Average age years, 35% female COPD 20-25% Dementia 6 10% Solid Cancer 10-15% Chronic kidney disease 25% Hemodialysis 3-4 % Among Medicare HF population, 40% have > 5 non-cardiac comorbidities Setoguchi et al Am H J 2007 Lee DS et al JAMA 2003 Braunstein et al JACC 2003
16 Not All Expectations Are Great Miss Haversham in Great Expectations, By Charles Dickens
17 Heart failure is a disease of the elderly Many patients with heart failure now survive to die of other diseases. There is a pyramid of decisions before resuscitation. Tough discussions today make difficult situations easier ahead.
18 Uncommon decisions Major Cardiac Surgery Decisions for almost everyone Regarding resuscitation
19 Potential Interventions Examples Examples of anticipated What If decisions for unanticipated outcomes High-risk cardiac surgery in hope of improving HF Less invasive interventions that may improve course of HF Adjunctive HF therapies with potential dependence CABG Unable to come off bypass Ventilator dependence Valve surgery Stroke Pericardial stripping PCI or percutaneous valve Need for urgent surgery? Temporary support devices (IABP, peructaneous VAD, ECMO) NON-CARDIAC Interventions for co-morbidities Unable to wean temporary support device? IV inotropes Unable to wean; move to MCS or discontinue? Temporary dialysis Irreversible renal failure? For symptomatic or functional benefit Delayed benefit only Joint replacement Hernia repair Resection of pulmonary nodule Asymptomatic aneurysm repair Screening colonoscopy Worsening heart failure, Ventilator dependence Stroke Worsening heart failure, Ventilator dependence Stroke
20 Not Likely to Die on the Table With Major Surgery Risk of stroke Risk of prolonged intubation Risk of renal failure Likelihood of prolonged convalescence, perhaps loss of independent living
21 Standardize Informed Consent for Advanced HF Procedures Background/indications Procedure Potential Benefits Potential Risks Alternative strategies Translation to patients should include examples : Of 100 patients like you, lived two years longer with Of 100 patients like you, had strokes that limited their ability to speak/walk/care for themselves Experience of your health care team $ Costs initial $ Costs per year Adapted from Krumholz, Informed Consent to Promote Patient-Centered Care. JAMA 2010:303:1190 Of 100 patients like you, rated their daily activity as near normal Because of your special conditions of , we may expect your outcomes to be better / worse than previous experiences. Expected duration of hospitalization Likelihood of discharge home vs to rehabilitation Months to full functional recovery Family experience
22 Limits to Logic Sometimes No is the right answer for the patient and his family. Godel s Incompleteness Theorem It is not possible to prove every statement that is true. Every logical system contains its own inconsistency. Prove or disprove the statement: This statement cannot be proven. Liar s Paradox: I am lying. True or false? Getting to No
23 Potential Interventions Examples Examples of anticipated What If decisions for unanticipated outcomes High-risk cardiac surgery in hope of improving HF Less invasive interventions that may improve course of HF Adjunctive HF therapies with potential dependence CABG Unable to come off bypass Ventilator dependence Valve surgery Stroke Pericardial stripping PCI or percutaneous valve Need for urgent surgery? Temporary support devices (IABP, peructaneous VAD, ECMO) NON-CARDIAC Interventions for co-morbidities Unable to wean temporary support device? IV inotropes Unable to wean; move to MCS or discontinue? Temporary dialysis Irreversible renal failure? For symptomatic or functional benefit Delayed benefit only Joint replacement Hernia repair Resection of pulmonary nodule Asymptomatic aneurysm repair Screening colonoscopy Worsening heart failure, Ventilator dependence Stroke Worsening heart failure, Ventilator dependence Stroke
24 Mortality Survival with Heart Failure On Inotropic Therapy - 13 Trials Months on Inotropic Therapy Placebo Randomized IV ino Uncontrolled IV ino Oral milrinone Class IV Univ Oregon COSI: Hershberger et al Circulation 2003, 108: 492-7
25 Only in the U.S. is death considered optional. George Wyse M.D. Director of Electrophysiology University of Calgary, Canada
26 Mortality (%) Time Horizon of Lives Saved by ICDs No benefit for first year Window of benefit Control Mortality Mortality with ICD ICD Lives Saved Benefit flat after 2-3 years Year Interim 1.7 Years MADIT II 3 Years DEFINITE 5 Years SCD-HeFT MADIT-II Moss AJ, Zerba W, Hall WJ, et al. N Engl J Med 2002;346: DEFINITE Ellenbogan KA, Levine JH, Berger RD, et al. Circulation 2006;113: SCD-HeFT Bardy GH, Lee KL, Mark DB, et al. N Engl J Med 2005;352:
27 Renal Disease and Repeated Hospitalization Interact to Predict Decreased Survival 4 Setoguchi et al. AHJ 2007 Median Survival (years) st admission 2nd admission 3rd admission 4th admission 0 CKD (n=3,264) No CKD (n=11,110) *CKD defined as estimated glumerular filtration rate < 60mL/min/1.73m2
28 Mortality Even With ICD Trial Data > data: 32% primary ICD are > 75 17% are > 80 years Non CV Other CV Sudden ACT Registry 4566 pts, 264 community centers Epstein et al, Heart Rhythm 2009,
29 2 nd Report of National ICD Registry 10,000 per month in U.S. Average age 68 years 31% over 75 years, 15% over 80 79% for primary prevention 77% symptomatic heart failure %I = 14 / II = 35/ III = 46/ IV = 5 66% have had prior HF hospitalization 12% had ICD during HF hospitalization Hammill et al 2008
30 ICDs During HF Hospitalization What Are We Doing?
31 Quality of Life vs Quality of Death? ICDs # per capita Is 3-10 X higher in U.S. than European countries US
32 You Don t Have to Have a Device Before You Die
33 Potential Interventions Examples Examples of anticipated What If decisions for unanticipated outcomes High-risk cardiac surgery in hope of improving HF Less invasive interventions that may improve course of HF Adjunctive HF therapies with potential dependence CABG Unable to come off bypass Ventilator dependence Valve surgery Stroke Pericardial stripping PCI or percutaneous valve Need for urgent surgery? Temporary support devices (IABP, peructaneous VAD, ECMO) Unable to wean temporary support device? IV inotropes Unable to wean; move to MCS or discontinue? Temporary dialysis Irreversible renal failure? NON-CARDIAC Interventions for co-morbidities For symptomatic or functional benefit Delayed benefit only Joint replacement Hernia repair Resection of pulmonary nodule Asymptomatic aneurysm repair Screening colonoscopy Worsening heart failure, Ventilator dependence Stroke Worsening heart failure, Ventilator dependence Stroke
34
35 Uncommon decisions Major Cardiac Surgery Decisions for almost everyone Regarding preferences for end of life
36 Old Conception Life Prolonging/Restorative Care Disease Progression End of Life Care D E A T H
37 A New Vision of Palliative Care Disease Modifying - Life Prolonging Rx Palliation of Symptoms Hospice Disease Progression Bereavement Diagnosis Death
38 The Hospital Admission Is Not The Time To Introduce End of Life Issues
39 Proposed Yearly Review for Patients With Advanced HF Perhaps at the time of influenza vaccination Re-evaluate current therapies and options Discuss prognosis in general terms Elicit goals and preferences Discuss what if with patient and family It is not the patients role to define the everything that they want. It is the physician s responsibility to frame the reasonable options.
40 Update of Discussion After Major Milestones Examples of Milestones ICD Shock Heart failure re-hospitalization Escalating maintenance diuretic doses Need to decrease or discontinue neurohormonal antagonists
41 Words Are Important Only? CMO = Comfort Measures Only
42 AND = Allow Natural Death Instituted by CEO Reverend Chuck Myers, Austin Texas, Now In Over 100 Hospitals
43
44 % Referred to Hospice 70 Trend in the Use of Hospice for Heart Failure Compared to Cancer HF EOL cohort (N=7,930) Cancer EOL cohort (N=7,565) Setoguchi et al AHA Calendar Year
45 % ER Visits within 30 Days of Death Trends in ER Visits Prior to Death Heart Failure Compared to Cancer HF EOL cohort (N=7,930) Cancer EOL cohort (N=7,565) Year
46 % Deaths in Acute Care Hospitals Trends in Hospital Deaths Heart Failure Compared to Cancer HF EOL cohort (N=7,930) Cancer EOL cohort (N=7,565) Calendar Year
47 Heart failure is a disease of the elderly Many patients with heart failure now survive to die of other diseases. There is a pyramid of decisions before resuscitation. Tough discussions today make difficult situations easier ahead.
48 Quality Life for the Elderly
49
Andrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationThe Interface of Cardiology and Palliative Medicine
The Interface of Cardiology and Palliative Medicine Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Mount Sinai School
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationEnd of Life Care in IJN Our journey. Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia
End of Life Care in IJN Our journey Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia End of Life Dying is final part of everyone journey in life Deaths used to occur
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationCase (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :
Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding Interim Vice Chair for Clinical Affairs Department of Medicine, University of Florida 1 2 Case (Coding Nightmare) 69
More informationThe Role of Palliative Care in the Management of Advanced Heart Failure
Disclosure The Role of Palliative Care in the Management of Advanced Heart Failure I have no conflict of interest to disclose. Darrell Craig MD Medical Director, Palliative Care Services St. Joseph Mercy
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationThe Role of Palliative Care in Readmission Reduction Steven Z. Pantilat, MD
The Role of Palliative Care in Readmission Reduction Steven Z. Pantilat, MD Professor of Clinical Medicine Alan M. Kates and John M. Burnard Endowed Chair in Palliative Care Director, Palliative Care Program
More informationThe Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities
The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationAbby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS
Abby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS Objectives Describe a team approach in the setting of critical illness Differentiate
More informationTri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM
Tri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM Faculty Disclosure Banner Baywood Medical Center -Chief of Staff FIFTH ANNUAL SYMPOSIUM NYHA class III-IV symptoms Clinical signs of fluid retention
More informationFacts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationICD deactivation Patient Journey
ICD deactivation Patient Journey Julia decourcey Consultant Nurse Kings College Hospital 05.05.10 Internal Cardiac Defibrillator Used in pts at high risk of sudden cardiac death ie EF > 30% Previous survivor
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationHeart Failure Therapies State of the Art: 2018
Heart Failure Therapies State of the Art: 2018 Andrew J. Sauer MD Associate Professor of Medicine Division Director Advanced Heart Failure Therapies & Cardiac Transplantation University of Kansas Medical
More informationHeart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital
Heart Failure 2012 Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital PRELOAD COWS Reduction in milk production INOTROPY & HEART RATE AFTERLOAD DISTRIBUTION NETWORK THE CLASSIC APPROACH
More informationWhen Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea
When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationTraining Program Directors' Symposium Session: Critical Care Cardiology Training
Training Program Directors' Symposium Session: Critical Care Cardiology Training David A. Morrow, MD, MPH, FACC Director, Levine Cardiac Intensive Care Unit Brigham and Women s Hospital, Boston, MA Our
More informationStage D Heart Failure. Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation
Stage D Heart Failure Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation What are the Stages of HF Stage Description Treatment A At risk for HF B Structural
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationWhere Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationReducing 30-day Rehospitalization for Heart Failure: An Attainable Goal?
Reducing 30-day Rehospitalization for Heart Failure: An Attainable Goal? Ileana L. Piña, MD, MPH Professor of Medicine, Epi/Biostats Case Western Reserve University Graduate VA Quality Scholar Cleveland
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationAdvanced Heart Failure: Patient Identification and Treatment Options. Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA
Advanced Heart Failure: Patient Identification and Treatment Options Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA Disclosures I have received honoraria from Thoratec Corporation/St. Jude
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationIntegrating Innovative Technologies into the Care of Cardiac Patients
Integrating Innovative Technologies into the Care of Cardiac Patients Marc J. Semigran MD Medical Director, Heart Failure & Cardiac Transplantation MGH Associate Professor Harvard Medical School Presenter
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationHeart Failure Vital steps for palliative care. Dr Karen J Hogg Glasgow Royal Infirmary
Heart Failure Vital steps for palliative care Dr Karen J Hogg Glasgow Royal Infirmary Overview Why is heart failure a problem? Why do we need integrated cardiology and palliative care services? Cardiology
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationRationale for Left Ventricular Support During Percutaneous Coronary Intervention
Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program
More informationMANAGEMENT OF CARDIOGENIC SHOCK
MANAGEMENT OF CARDIOGENIC SHOCK CASE PRESENTATION 37 year old Dutch female No known coronary artery disease risk factors 1 week post partum at time of presentation (G3P3) after an uncomplicated normal
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationCitation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute
What is New in the 2013 ACC/AHA HF Guideline Dimensions in Heart and Vascular Care Penn State Heart and Vascular nstitute Friday October 18, 2013 Barry S. Clemson, MD Associate Professor of Medicine Penn
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationAbbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationShared decision making for advanced heart failure has
AHA Scientific Statement Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association Endorsed by Heart Failure Society of America, American Association of Heart
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationWalking together: Palliative Care and heart failure.
Walking together: Palliative Care and heart failure. St Paul's Hospital Heart Function Supportive Care Clinic Cindy Nordquist MN-NP(F) Objectives Review heart failure. Review palliative care/ palliative
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationThe Role of Information Technology in Disease Management: A Case for Heart Failure
The Role of Information Technology in Disease Management: A Case for Heart Failure Teresa De Peralta, MSN, APN-C Heart Failure Product Workflow Consultant Medtronic Population Management Level 3: As patient
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationGiving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationSurgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018
Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report May 2018 Prepared by the Canadian Cardiovascular Society (CCS)/Canadian Society of Cardiac Surgeons (CSCS) Cardiac
More information